Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Clinical Science and Education, Södersjukhuset, Stockholm, Sweden; Astrid Lindgren Children's Hospital, Karolinska University Hospital, Huddinge, Sweden.
Clin Gastroenterol Hepatol. 2021 May;19(5):930-938.e8. doi: 10.1016/j.cgh.2020.04.047. Epub 2020 Apr 25.
BACKGROUND & AIMS: Little is known about the natural history of childhood recurrent abdominal pain (RAP). We investigated the prevalence and progression of childhood RAP and its association with Rome III abdominal pain-related functional gastrointestinal disorders (AP-FGID) and irritable bowel syndrome (IBS) during adolescence.
We collected data from a prospective population-based birth cohort study of 4089 children, born from 1994 through 1996 in Sweden. We analyzed data from 2455 children with complete follow-up evaluation at ages 1, 2, 12, and 16 years and no parent-reported diagnoses of inflammatory bowel diseases or celiac disease at ages 12 or 16 years. A subpopulation of 2374 children who had answered questions based on the Rome III criteria at age 16 years was identified. We assessed RAP at 3 assessment points and defined it as parent-reported attacks of colic in early childhood (1-2 years) and as self-reported weekly abdominal pain at ages 12 years and 16 years. AP-FGID at age 16 years was defined according to the Rome III criteria.
RAP was reported by 26.2% of children on at least 1 of 3 assessment points, of which 11.3% reported symptoms more than once. Children with RAP at 12 years had persistent symptoms at 16 years in 44.9% of cases and increased risks for RAP (relative risk, 2.2; 95% CI, 1.7-2.8), any AP-FGID (relative risk, 2.6; 95% CI, 1.9-3.6), and IBS (relative risk, 3.2; 95% CI, 2.0-5.1) at 16 years. Early childhood RAP was not associated significantly with any outcome.
RAP affects many children from early childhood through age 16 years, but most children do not have persistent symptoms throughout childhood. RAP at age 12 years is a risk factor for RAP, any Rome III AP-FGID, and IBS, at age 16 years.
儿童复发性腹痛(RAP)的自然病史知之甚少。我们研究了儿童 RAP 的患病率和进展情况,以及其与青少年时期罗马 III 腹痛相关功能性胃肠疾病(AP-FGID)和肠易激综合征(IBS)的关联。
我们从瑞典 1994 年至 1996 年出生的一项前瞻性人群出生队列研究中收集数据。我们分析了 2455 名儿童的数据,这些儿童在 1、2、12 和 16 岁时完成了完整的随访评估,且在 12 岁和 16 岁时无父母报告的炎症性肠病或乳糜泻诊断。确定了一个亚组,该亚组由 2374 名在 16 岁时根据罗马 III 标准回答问题的儿童组成。我们在 3 个评估点评估 RAP,并将其定义为父母报告的幼儿期绞痛发作(1-2 岁)和 12 岁和 16 岁时自我报告的每周腹痛。16 岁时的 AP-FGID 根据罗马 III 标准定义。
在至少 3 个评估点中有 26.2%的儿童报告存在 RAP,其中 11.3%的儿童报告症状不止一次。12 岁时存在 RAP 的儿童,44.9%的病例在 16 岁时有持续性症状,且存在 RAP(相对风险,2.2;95%CI,1.7-2.8)、任何罗马 III AP-FGID(相对风险,2.6;95%CI,1.9-3.6)和 IBS(相对风险,3.2;95%CI,2.0-5.1)的风险增加。幼儿期 RAP 与任何结果均无显著相关性。
RAP 影响许多儿童从幼儿期到 16 岁,但大多数儿童在整个儿童期都没有持续性症状。12 岁时的 RAP 是 16 岁时 RAP、任何罗马 III AP-FGID 和 IBS 的危险因素。